Trial site
Hospital Quironsalud Sagrado Corazon
Sevilla, 41013, SpainNot linked to an institution yet
- 19running trials
- 15closed trials
The trials here
What the 34 trials at this site are about, from their registry records.
- Phase
- Phase 321 trials
- Phase 212 trials
- Phase 41 trial
- Status
- Completed15 trials
- Active, not recruiting11 trials
- Recruiting7 trials
- Not yet recruiting1 trial
- Lead sponsor
- Janssen Research & Development, LLC4 trials
- MedSIR4 trials
- Sun Pharmaceutical Industries Limited3 trials
- AstraZeneca2 trials
- MoonLake Immunotherapeutics AG2 trials
- and 17 more
Running trials
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058· Phase 3· Takeda· Source
Not yet recruiting
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Recruiting
RANDOMISED, MULTICENTRE, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MONTELUKAST VS. PLACEBO IN PATIENTS WITH EROSIVE/INFLAMMATORY OSTEOARTHRITIS OF THE HANDS. MOTHER Study.
2025-521802-17-00· Phase 3· Farmalider S.A.· Source
Recruiting
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
NCT06486883· Phase 2· MedSIR· Source
Active, not recruiting
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Recruiting
A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
2023-507097-41-01· Phase 3· Shanghai Junshi Biosciences Co. Ltd.· Source
Active, not recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496· Phase 3· Takeda· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948· Phase 3· MedSIR· Source
Active, not recruiting
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
NCT06172127· Phase 2· MedSIR· Source
Active, not recruiting
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
NCT05672576· Phase 3· Viatris Innovation GmbH· Source
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654· Phase 3· Gilead Sciences· Source
Active, not recruiting
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04991116· Phase 3· Sun Pharmaceutical Industries Limited· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257· Phase 3· Shanghai Henlius Biotech· Source
Active, not recruiting
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210· Phase 4· Janssen Research & Development, LLC· Source
Enrolling by invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322· Phase 3· UCB Biopharma SRL· Source
Active, not recruiting
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.
NCT04053322· Phase 2· UNICANCER· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
NCT07225829· Phase 2· 4Moving Biotech· Source
Active, not recruiting
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC
NCT06219317· Phase 2· European Organisation for Research and Treatment of Cancer - EORTC· Source
Completed
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome
NCT06312020· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source
Completed
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
NCT05865990· Phase 2· MedSIR· Source
Completed
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
NCT05586971· Phase 3· LG Chem· Source
Completed
The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
NCT05162586· Phase 2· EMD Serono Research & Development Institute, Inc.· Source
Completed
Advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer
NCT05207709· Phase 3· Solti Group· Source
Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Subjects with Active Psoriatic Arthritis II (INSPIRE 2)
2024-512142-42-00· Phase 3· Sun Pharmaceutical Industries Limited· Source
Completed
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
NCT04936308· Phase 3· Janssen Research & Development, LLC· Source
Completed
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
NCT04736173· Phase 2· Arcus Biosciences, Inc.· Source
Completed
Clinical Trial to evaluate the efficacy of immunotherapy in a subset of Hormonal Receptor-positive/HER2-negative advanced breast cancer
patients who have progressed to standard therapy.
2023-508546-17-00· Phase 2· Solti Group· Source
Completed
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
NCT04314544· Phase 3· Sun Pharmaceutical Industries Limited· Source
Active, not recruiting
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
NCT04305496· Phase 3· AstraZeneca· Source
Completed
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT03563716· Phase 2· Genentech, Inc.· Source
Completed
Clinical trial to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo versus fulvestrant (FaslodexTM) 500mg with PD-0332991 (Palbociclib), randomly assigned, as first line treatment for postmenopausal women with hormone receptor-positive metastatic breast cancer, who have completed at least 5 years of hormonal therapy and remained disease free for more than 12 months following its completion or who have metastatic disease diagnosed from the beginning.
2024-516132-10-00· Phase 2· Fundacion Grupo Espanol De Investigacion En Cancer De Mama· Source
Report an error